AstraZeneca - On the Verge of a Breakdown - Respiratory Portfolio (Symbicort and Pulmicort) Threatened by Generics
![](/report_cover/5562/astrazeneca-on-verge-of-a-breakdown-respiratory-portfolio-symbicort-n-pulmicort-threatened-by-generics_en.gif)
The respiratory portfolio of AZN which so far has withstood generics attack, is now giving away. Yesterday’s court ruling invalidating pulmicort respule patent and Teva filing a MAA in Europe for a generic equivalent of Symbicort has really shaken AZN base business. In addition recently Apotex announced invalidation of AZN Crestor patent in the Australia ($350m annual sales in 2012). We revise our 2013 core EPS estimate from $4.7 per share to $4.6 per share.
Companies mentioned
AstraZeneca
Companies mentioned
AstraZeneca